Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
7.35 USD | +43.84% | +39.47% | +46.41% |
04-26 | Transcript : ImmunityBio, Inc. - Special Call | |
04-25 | ImmunityBio, Inc. Announces Positive Overall Survival Results of Anktiva Combined with Checkpoint Inhibitors in Non-Small Cell Lung Cancer | CI |
Sales 2024 * | 9.68M 772M | Sales 2025 * | 84.68M 6.75B | Capitalization | 4.98B 397B |
---|---|---|---|---|---|
Net income 2024 * | -459M -36.59B | Net income 2025 * | -305M -24.32B | EV / Sales 2024 * | 514 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 58.8 x |
P/E ratio 2024 * |
-9.67
x | P/E ratio 2025 * |
-13.7
x | Employees | 628 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 20.33% |
Latest transcript on ImmunityBio, Inc.
1 day | +43.84% | ||
1 week | +39.47% | ||
Current month | +36.87% | ||
1 month | +36.87% | ||
3 months | +123.40% | ||
6 months | +196.37% | ||
Current year | +46.41% |
Managers | Title | Age | Since |
---|---|---|---|
Richard Adcock
CEO | Chief Executive Officer | 55 | 30/09/20 |
Founder | 71 | 30/11/14 | |
David Sachs
DFI | Director of Finance/CFO | 46 | 30/06/19 |
Members of the board | Title | Age | Since |
---|---|---|---|
Founder | 71 | 30/11/14 | |
Cheryl L. Cohen
BRD | Director/Board Member | 58 | 31/05/19 |
Wesley Clark
BRD | Director/Board Member | 78 | 23/02/21 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.04% | 0 M€ | 0.00% | - | |
0.04% | 0 M€ | 0.00% | - | |
0.02% | 2 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
26/04/24 | 7.35 | +43.84% | 40,280,221 |
25/04/24 | 5.11 | +6.02% | 8,556,026 |
24/04/24 | 4.82 | -12.20% | 7,938,366 |
23/04/24 | 5.49 | +11.13% | 30,697,001 |
22/04/24 | 4.94 | -6.26% | 5,468,509 |
Delayed Quote Nasdaq, April 26, 2024 at 09:00 pm
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+46.41% | 4.98B | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.73B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- IBRX Stock